Drug Trial Radar · NCT07294365
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 15, 2026
Primary completion
Jul 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to different dose groups.
Conditions
- Immune Thrombocytopenia (ITP)
Interventions
DZD8586 dose level 1Drug
DZD8586 will be administered orally in a 28-day cycle.
DZD8586 dose level 2Drug
DZD8586 will be administered orally in a 28-day cycle.
DZD8586 dose level 3Drug
DZD8586 will be administered orally in a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (4 weeks)Time frame: within 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.